DeCure for Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2013 study of 152 preterm neonates with respiratory distress syndrome and 125 preterm controls (all born before 37 weeks) in a Turkish population examined the eNOS gene Glu298Asp polymorphism. Genotype frequencies for Glu/Glu, Glu/Asp, and Asp/Asp were 32.9%, 65.1%, and 2.0% in the patient group versus 35.2%, 59.2%, and 5.6% in controls; the overall difference was not statistically significant (P > 0.05). When infants were stratified by gestational age (24–30 weeks versus 31–36 weeks), the Glu/Glu genotype and Glu allele were significantly more frequent in the RDS groups, while the Glu/Asp genotype and Asp allele were significantly less frequent (P < 0.05). Sex-specific effects were also noted: Asp allele frequency was significantly higher in boys with RDS, and Glu allele frequency was significantly higher in girls with RDS (P < 0.05). The authors concluded that gestational age-related differences in eNOS Glu298Asp genotype frequencies were associated with RDS in this Turkish population.
A 2016 review chapter notes that approximately 10% of neonates require respiratory support after delivery, up to 1% need resuscitation, and respiratory distress is the most frequent cause of neonatal intensive care unit admission. It emphasises that individual management strategies are the main task in NICUs and that unrecognised or unmanaged respiratory distress can escalate to respiratory failure and cardiopulmonary arrest. The chapter presents an update on evaluation, differential diagnosis, and management according to the protocol of Ankara University Children’s Hospital NICU.
A 2013 review of genetic association studies in Korean preterm infants summarises that respiratory distress syndrome and bronchopulmonary dysplasia remain major acute and chronic postnatal lung diseases in the NICU, that they are multifactorial with genetic contributions, and that specific variants in genes regulating pulmonary development, structure, function, inflammation, or host defence may be risk factors. The review analyses genetic differences among study populations to identify candidate genes for susceptibility in Korean preterm infants.
No drug treatment is tested or recommended in any of these abstracts. The genetic association reported in the Turkish study is modest, stratified by gestational age and sex, and not replicated in a separate population. What is missing is a prospective trial that tests whether modulating eNOS activity alters clinical outcomes in preterm infants with respiratory distress, and any validated biomarker or genetic test that could stratify patients for such an intervention. The 2016 review provides no new trial data, only protocol-based management advice.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric Pulmonology · 2013 · 9 citations · open access
Endothelial<scp>NOS</scp>gene Glu298<scp>A</scp>sp polymorphism in preterm neonates with respiratory distress syndrome
AbstractRATIONALE: Respiratory Distress Syndrome (RDS) due to prematurity is one of the most important causes of morbidity and mortality in Neonatal Intensive Care Units. According to few studies in recent years, endothelial nitric oxide synthase (eNOS) gene polymorphisms are found to be partially responsible for liability to RDS. The purpose of this study was to determine the association between eNOS gene polymorphism and RDS in preterm neonates. PATIENTS AND METHODS: The patient group consisted of 152 premature neonates born before 37 weeks of gestation and diagnosed as RDS. The control group consisted of 125 premature neonates born before 37 weeks of gestation, but was not diagnosed as RDS. Genomic DNA from patients and controls was analyzed by polymerase chain reaction. RESULTS: It was found that Glu/Glu, Glu/Asp, and Asp/Asp genotype frequencies of the eNOS gene polymorphism were 35.2%, 59.2%, and 5.6% of the control group, and 32.9%, 65.1%, and 2.0% of the patient group, respectively (P > 0.05). However, significant increases in Glu/Glu genotype and Glu allele frequencies were noted in the RDS groups when the preterm neonates were divided into two groups (24-30 weeks and 31-36 weeks) by gestational age. Additionally, Glu/Asp genotype and Asp allele were markedly less frequent among the RDS groups (P < 0.05). Asp allele frequency in boys and Glu allele frequency in girls were significantly high in RDS group (P < 0.05). CONCLUSIONS: These data suggest that there were significant gestational age-related differences between RDS and control groups in terms of Glu298Asp polymorphism. Therefore, RDS seems to develop with alterations in eNOS Glu298Asp genotype frequencies in the Turkish population.
Respiratory Distress and Management Strategies in the Newborn
AbstractApproximately 10% of neonates require respiratory support immediately after delivery due to transitional problems or respiratory disorders, and up to 1% of neonates are in need of resuscitation. Respiratory distress is the most frequent cause of neonatal intensive care unit (NICU) admission, and the individual management strategies should be the main task in NICUs for these infants. Regardless of the cause, if not recognized and managed in advance, respiratory distress can escalate to respiratory failure and cardiopulmonary arrest. This chapter explores the evaluation and differential diagnosis of respiratory distress in neonates and presents an update on management strategies according to the protocol of Ankara University Children’s Hospital Neonatal Intensive Care Unit.
Neonatal Medicine · 2013 · 1 citations · open access
Association between Respiratory Disorders and Candidate Genes in Korean Newborn Infants
AbstractRespiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD) remain major acute and chronic postnatal lung diseases in the Neonatal Intensive Care Unit. RDS and BPD are multifactorial diseases influenced by genetic factors. Specific genetic variants contributing to the regulation of pulmonary development, structure and function or inflammatory response, and host defense mechanism can be risk factors for the development of RDS and/or BPD. This review summarizes recent association studies of genetic polymorphisms with RDS and BPD. In addition, we analyze the genetic differences among various study populations to identify potential candidate genes for susceptibility to RDS and BPD in Korean preterm infants.
AbstractRespiratory pathologies, along with congenital cardiac diseases, represent the main etiologies of neonatal disorders. Neonatal respiratory distress syndrome embraces several pathologies that share respiratory impairment as its main clinical manifestation. Epidemiological and risk factors for respiratory disorders, such as weeks of gestation accomplished before birth and maternal comorbidities, have been identified during the last decades. However, similar acute clinical manifestations, as well as laboratory and radiological findings, lack comprehension, which might lead to an incorrect diagnosis and delayed optimal treatment. Hyaline membrane disease, transient tachypnea of the newborn, and meconium aspiration syndrome represent the three most frequent types of neonatal respiratory distress syndrome. In this paper, we describe the risk factors and pathophysiology of each disease and compare clinical manifestations, as well as laboratory and radiological findings between them. For this purpose, we analized a key termed based literature review which include Systematic Reviews, Metanalysis, case reports and book chapters as well as private hospitals epidemiologic statistic reports. Finally, we present a differential diagnosis algorithm which can be used to identify which respiratory distress syndrome the newborn manifests and consequently give prompt and optimal treatment.
Advances in the treatment of neonatal acute respiratory distress syndrome
AbstractAcute respiratory distress syndrome (ARDS) caused by various reasons is a common severe neonatal clinical disease.The cure rate of the ARDS in newborns increases with the constantly progress of the neonatal intensive care and diagnosis medical technology.However, the motality of ARDS in newborn infants is still very high, about 30%-40%.There is no special therapy with neonatal ARDS and comprehensive treatment is adopted mainly according to its pathophysiologic change and clinical manifestation.The review will summarize the advances in the treatment of neonatal ARDS.
Key words:
Acute respiratory distress syndrome; Treatment; Infant, newborn
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
